<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Current Computer-Aided Drug Design</journal-id><journal-title-group><journal-title xml:lang="en">Current Computer-Aided Drug Design</journal-title><trans-title-group xml:lang="ru"><trans-title>Current Computer-Aided Drug Design</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1573-4099</issn><issn publication-format="electronic">1875-6697</issn><publisher><publisher-name xml:lang="en">Bentham Science</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">644006</article-id><article-id pub-id-type="doi">10.2174/1573409919666230310144550</article-id><article-categories><subj-group subj-group-type="toc-heading"><subject>Chemistry</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">In silico Analysis of Natural Inhibitors against HPV E6 Protein</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Vani</surname><given-names>Vemula</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Venkateshappa</surname><given-names>Snehalatha</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Nishitha</surname><given-names>Rachel</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name><surname>Shashidhar</surname><given-names>Hima</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name><surname>Hegde</surname><given-names>Arpitha</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name><surname>Alagumuthu</surname><given-names>Manikandan</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff id="aff1"><institution>Department of Microbiology, MS Ramaiah College of Arts, Science and Commerce,</institution></aff><aff id="aff2"><institution>Department of Microbiology, MS Ramaiah College of Arts, Science and Commerce</institution></aff><aff id="aff3"><institution>Department of Microbiology,, MS Ramaiah College of Arts Science &amp; Commerce</institution></aff><pub-date date-type="pub" iso-8601-date="2024-03-01" publication-format="electronic"><day>01</day><month>03</month><year>2024</year></pub-date><volume>20</volume><issue>3</issue><issue-title xml:lang="ru"/><fpage>303</fpage><lpage>311</lpage><history><date date-type="received" iso-8601-date="2025-01-07"><day>07</day><month>01</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Bentham Science Publishers</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Bentham Science Publishers</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://rjeid.com/1573-4099/article/view/644006">https://rjeid.com/1573-4099/article/view/644006</self-uri><abstract xml:lang="en"><p id="idm46041443774544">Background:Drug re-purposing is one of the cost-effective methods to establish novel therapeutics against many diseases. Established natural products are collected from databases and used to potentially screen them against HPV E6 protein, a critical viral protein.</p><p id="idm46041443778544">Objective:This study aims to design potential small molecule inhibitors against HPV E6 protein using structure-based approaches. Ten natural anti-cancerous compounds (Apigenin, Baicalein, Baicalin, Ponicidin, Oridonin, Lovastatin, Triterpenoid, Narirutin, Rosmarinic Acid, and Xanthone) were selected by review of the literature.</p><p id="idm46041443782512">Methods:These compounds were screened using Lipinski Rule of Five. Out of ten compounds, seven were found to satisfy Rule of five. Docking of these seven compounds was carried out using AutoDock software and corresponding Molecular Dynamics Simulations were performed by GROMACS.</p><p id="idm46041443787568">Results:Among the seven compounds docked with the E6 target protein, six compounds showed lesser binding energy than the reference compound, Luteolin. The three-dimensional structures of E6 protein and the corresponding ligand complexes were visualised and analysed using PyMOL whereas the two-dimensional images of protein-ligand interactions were obtained by LigPlot+ software to study the specific interactions. ADME analysis using SwissADME software revealed that all the compounds except Rosmarinic acid have good gastrointestinal absorption and solubility characteristics while Xanthone and Lovastatin showed blood brain barrier penetration properties. Considering the binding energy and ADME analysis, Apigenin and Ponicidin are found to be most suitable for de novo designing of potential inhibitors against the HPV16 E6 protein.</p><p id="idm46041443796944">Conclusion:Further, synthesis and characterization of these potential HPV16 E6 inhibitors will be carried out and their functional evaluation using cell culture-based assays will be undertaken.</p></abstract><kwd-group xml:lang="en"><kwd>ADME</kwd><kwd>anti-cervical cancer</kwd><kwd>HPV16 E6</kwd><kwd>natural products</kwd><kwd>small molecule inhibitors</kwd><kwd>molecular dynamics simulations.</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Allison, D.B.; Maleki, Z. HPV-related head and neck squamous cell carcinoma: An update and review. J. Am. Soc. Cytopathol., 2016, 5(4), 203-215. doi: 10.1016/j.jasc.2015.12.001 PMID: 31042510</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Kombe Kombe, A.J.; Li, B.; Zahid, A.; Mengist, H.M.; Bounda, G.A.; Zhou, Y.; Jin, T. Epidemiology and burden of human papillomavirus and related diseases, molecular pathogenesis, and vaccine evaluation. Front. Public Health, 2021, 8, 552028. doi: 10.3389/fpubh.2020.552028 PMID: 33553082</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Cheng, L.; Wang, Y.; Du, J. Human papillomavirus vaccines: An updated review. Vaccines, 2020, 8(3), 391. doi: 10.3390/vaccines8030391 PMID: 32708759</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Akhatova, A.; Azizan, A.; Atageldiyeva, K.; Ashimkhanova, A.; Marat, A.; Iztleuov, Y.; Suleimenova, A.; Shamkeeva, S.; Aimagambetova, G. Prophylactic human papillomavirus vaccination: From the origin to the current state. Vaccines, 2022, 10(11), 1912. doi: 10.3390/vaccines10111912 PMID: 36423008</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Hampson, L.; Martin-Hirsch, P.; Hampson, I.N. An overview of early investigational drugs for the treatment of human papilloma virus infection and associated dysplasia. Expert Opin. Investig. Drugs, 2015, 24(12), 1529-1537. doi: 10.1517/13543784.2015.1099628 PMID: 26457651</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Mittal, S.; Banks, L. Molecular mechanisms underlying human papillomavirus E6 and E7 oncoprotein-induced cell transformation. Mutat. Res. Rev. Mutat. Res., 2017, 772, 23-35. doi: 10.1016/j.mrrev.2016.08.001 PMID: 28528687</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Pal, A.; Kundu, R. Human papillomavirus E6 and E7: The cervical cancer hallmarks and targets for therapy. Front. Microbiol., 2020, 10, 3116. doi: 10.3389/fmicb.2019.03116 PMID: 32038557</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Howie, H.L.; Katzenellenbogen, R.A.; Galloway, D.A. Papillomavirus E6 proteins. Virology, 2009, 384(2), 324-334. doi: 10.1016/j.virol.2008.11.017 PMID: 19081593</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Martinez-Zapien, D.; Ruiz, F.X.; Poirson, J.; Mitschler, A.; Ramirez, J.; Forster, A.; Cousido-Siah, A.; Masson, M.; Pol, S.V.; Podjarny, A.; Travé, G.; Zanier, K. Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53. Nature, 2016, 529(7587), 541-545. doi: 10.1038/nature16481 PMID: 26789255</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Scheffner, M.; Münger, K.; Byrne, J.C.; Howley, P.M. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc. Natl. Acad. Sci. USA, 1991, 88(13), 5523-5527. doi: 10.1073/pnas.88.13.5523 PMID: 1648218</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Zanier, K.; Charbonnier, S.; Sidi, A.O.M.O.; McEwen, A.G.; Ferrario, M.G.; Poussin-Courmontagne, P.; Cura, V.; Brimer, N.; Babah, K.O.; Ansari, T.; Muller, I.; Stote, R.H.; Cavarelli, J.; Vande Pol, S.; Travé, G. Structural basis for hijacking of cellular LxxLL motifs by papillomavirus E6 oncoproteins. Science, 2013, 339(6120), 694-698. doi: 10.1126/science.1229934 PMID: 23393263</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Malecka, K.A.; Fera, D.; Schultz, D.C.; Hodawadekar, S.; Reichman, M.; Donover, P.S.; Murphy, M.E.; Marmorstein, R. Identification and characterization of small molecule human papillomavirus E6 inhibitors. ACS Chem. Biol., 2014, 9(7), 1603-1612. doi: 10.1021/cb500229d PMID: 24854633</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Zanier, K.; Stutz, C.; Kintscher, S.; Reinz, E.; Sehr, P.; Bulkescher, J.; Hoppe-Seyler, K.; Travé, G.; Hoppe-Seyler, F. The E6AP binding pocket of the HPV16 E6 oncoprotein provides a docking site for a small inhibitory peptide unrelated to E6AP, indicating druggability of E6. PLoS One, 2014, 9(11), e112514. doi: 10.1371/journal.pone.0112514 PMID: 25383876</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Donà, M.G.; Di Bonito, P.; Chiantore, M.V.; Amici, C.; Accardi, L. Targeting human papillomavirus-associated cancer by oncoprotein-specific recombinant antibodies. Int. J. Mol. Sci., 2021, 22(17), 9143. doi: 10.3390/ijms22179143 PMID: 34502053</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Baleja, J.D.; Cherry, J.J.; Liu, Z.; Gao, H.; Nicklaus, M.C.; Voigt, J.H.; Chen, J.J.; Androphy, E.J. Identification of inhibitors to papillomavirus type 16 E6 protein based on three-dimensional structures of interacting proteins. Antiviral Res., 2006, 72(1), 49-59. doi: 10.1016/j.antiviral.2006.03.014 PMID: 16690141</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Cherry, J.J.; Rietz, A.; Malinkevich, A.; Liu, Y.; Xie, M.; Bartolowits, M.; Davisson, V.J.; Baleja, J.D.; Androphy, E.J. Structure based identification and characterization of flavonoids that disrupt human papillomavirus-16 E6 function. PLoS One, 2013, 8(12), e84506. doi: 10.1371/journal.pone.0084506 PMID: 24376816</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>DiMasi, J.A.; Grabowski, H.G.; Hansen, R.W. Innovation in the pharmaceutical industry: New estimates of R&amp;D costs. J. Health Econ., 2016, 47, 20-33. doi: 10.1016/j.jhealeco.2016.01.012 PMID: 26928437</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Murgueitio, M.S.; Bermudez, M.; Mortier, J.; Wolber, G. In silico virtual screening approaches for anti-viral drug discovery. Drug Discov. Today. Technol., 2012, 9(3), e219-e225. doi: 10.1016/j.ddtec.2012.07.009 PMID: 24990575</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Wang, H.; Oo Khor, T.; Shu, L.; Su, Z.Y.; Fuentes, F.; Lee, J.H.; Tony Kong, A-N. Plants vs. cancer: A review on natural phytochemicals in preventing and treating cancers and their druggability. Anticancer. Agents Med. Chem., 2012, 12(10), 1281-1305. doi: 10.2174/187152012803833026 PMID: 22583408</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Sagar, S.M. Natural health products that inhibit angiogenesis: A potential source for investigational new agents to treat cancer-Part 1. Current oncology, 2006, 13(1), 14-26.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Lin, C.K.; Liu, S.T.; Chang, C.C.; Huang, S.M. Regulatory mechanisms of fluvastatin and lovastatin for the p21 induction in human cervical cancer HeLa cells. PLoS One, 2019, 14(4), e0214408. doi: 10.1371/journal.pone.0214408 PMID: 30939155</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Rawson, N.E.; Ho, C-T.; Li, S. Efficacious anti-cancer property of flavonoids from citrus peels. Food Sci. Hum. Wellness, 2014, 3(3-4), 104-109. doi: 10.1016/j.fshw.2014.11.001</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Vieira, L.M.M.; Kijjoa, A. Naturally-occurring xanthones: Recent developments. Curr. Med. Chem., 2005, 12(21), 2413-2446. doi: 10.2174/092986705774370682 PMID: 16250871</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Beutner, K.R.; Ferenczy, A. Therapeutic approaches to genital warts. Am. J. Med., 1997, 102(5A), 28-37. doi: 10.1016/S0002-9343(97)00181-2 PMID: 9217660</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Alagumuthu, M.; Muralidharan, V.P.; Andrew, M.; Ahmed, M.H.; Iyer, S.K.; Arumugam, S. Computational approaches to develop isoquinoline based antibiotics through DNA gyrase inhibition mechanisms unveiled through antibacterial evaluation and molecular docking. Mol. Inform., 2018, 37(12), 1800048. doi: 10.1002/minf.201800048 PMID: 30051592</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Alagumuthu, M.; Arumugam, S. Molecular docking, discovery, synthesis, and pharmacological properties of new 6-substituted-2-(3-phenoxyphenyl)-4-phenyl quinoline derivatives; an approach to developing potent DNA gyrase inhibitors/antibacterial agents. Bioorg. Med. Chem., 2017, 25(4), 1448-1455. doi: 10.1016/j.bmc.2017.01.007 PMID: 28094220</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Sanner, Michel F. A programming language for software integration and development. J. Mol. Graphics Mod., 1999, 57-61.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Lilkova, E. The PyMOL Molecular Graphics System, Version 2.0 Schrodinger, LLC. 2015.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Wallace, A.C.; Laskowski, R.A.; Thornton, J.M. LIGPLOT: A program to generate schematic diagrams of protein-ligand interactions. Protein Eng. Des. Sel., 1995, 8(2), 127-134. doi: 10.1093/protein/8.2.127 PMID: 7630882</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov, I.N.; Bourne, P.E. The protein data bank. Nucleic Acids Res., 2000, 235-242.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Jayaram, B.; Singh, T.; Mukherjee, G.; Mathur, A.; Shekhar, S.; Shekhar, V. Sanjeevini: A freely accessible web-server for target directed lead molecule discovery. BMC Bioinformatics, 2012, 13(Suppl. 17), S7. doi: 10.1186/1471-2105-13-S17-S7 PMID: 23282245</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Lipinski, C.A. Lead- and drug-like compounds: The rule-of-five revolution. Drug Discov. Today. Technol., 2004, 1(4), 337-341. doi: 10.1016/j.ddtec.2004.11.007 PMID: 24981612</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>OBoyle, N.M.; Banck, M.; James, C.A.; Morley, C.; Vandermeersch, T.; Hutchison, G.R. Open Babel: An open chemical toolbox. J. Cheminform., 2011, 3(1), 33. doi: 10.1186/1758-2946-3-33 PMID: 21982300</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Alagumuthu, M.; Rajpoot, S.; Baig, M.S. Structure-based design of novel peptidomimetics targeting the SARS-CoV-2 spike protein. Cell. Mol. Bioeng., 2021, 14(2), 177-185. doi: 10.1007/s12195-020-00658-5 PMID: 33072222</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Oostenbrink, C.; Villa, A.; Mark, A.E.; Van Gunsteren, W.F. A biomolecular force field based on the free enthalpy of hydration and solvation: The GROMOS force-field parameter sets 53A5 and 53A6. J. Comput. Chem., 2004, 25(13), 1656-1676. doi: 10.1002/jcc.20090 PMID: 15264259</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Stefl, P. What is log Pow? The O/W partition coefficient in SDSs. , 2017. Available From: https://www.gesi.de/en/blog/2017/02/06/what-is-log-pow-the-o-w-partition-coefficient-in-sdss/</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Fagerholm, U.; Hellberg, S.; Spjuth, O. Advances in predictions of oral bioavailability of candidate drugs in man with new machine learning methodology. Molecules, 2021, 26(9), 2572. doi: 10.3390/molecules26092572 PMID: 33925103</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Middha, S.K.; Goyal, A.K.; Faizan, S.A.; Sanghamitra, N.; Basistha, B.C.; Usha, T. In silico based combinatorial pharmacophore modelling and docking studies of GSK-3β and GK inhibitors of Hippophae. J. Biosci., 2013, 38(4), 805-814. doi: 10.1007/s12038-013-9367-y PMID: 24287660</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Negi, J.S.; Bisht, V.K.; Singh, P.; Rawat, M.S.M.; Joshi, G.P. Naturally occurring xanthones: chemistry and biology. J. Appl. Chem., 2013, 621459, 2013. doi: 10.1155/2013/621459</mixed-citation></ref></ref-list></back></article>
